Company Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 7, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 197 |
| CEO | Vikram Karnani |
Contact Details
Address: 100 Technology Center Drive, Suite 300 Stoughton, Massachusetts 02072 United States | |
| Phone | 781 713 3699 |
| Website | collegiumpharma.com |
Stock Details
| Ticker Symbol | COLL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267565 |
| CUSIP Number | 19459J104 |
| ISIN Number | US19459J1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Colleen Tupper | Executive Vice President and Chief Financial Officer |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 8-K/A | [Amend] Current report |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SCHEDULE 13G | Filing |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 144 | Filing |
| Sep 13, 2024 | 144 | Filing |
| Sep 6, 2024 | 144 | Filing |
| Sep 5, 2024 | 144 | Filing |